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Arising from Inflammatory Bowel Disease
Adam D. Toll1, Bruce M. Boman2, Juan P. Palazzo1
1

Department of Pathology, 2Medical Genetics and Cancer Prevention, Thomas Jefferson University Hospital, Philadelphia PA

BACKGROUND
The cancer stem cell (CSC) hypothesis proposes a
relatively small population of neoplastic cells have the
unique ability to initiate and sustain tumoral growth.
Detection of cancer stem cells has been performed
with a variety of markers, most notably aldehyde
dehydrogenase (ALDH1), responsible for catalyzing the
irreversible oxidation of aromatic aldehydes to their
corresponding carboxylic acids. Prior work using
xenograft models has shown ALDH1+ cells from both
colorectal adenocarcinoma (CRC) and inflammatory
bowel disease (IBD) are capable of promoting tumorigenesis in mice. We hope to expand on previous work
through the examination of ALDH1 expression in
dysplastic lesions from surgical resections for IBD,
thereby illustrating the importance of CSCs in the
development of neoplasia arising from an inflammatory
background. The distinction between inflammatory
change and dysplasia can be difficult, and has significant
patient management implications. Increasing levels of
ALDH1 may help identify dysplasia, and confirm the
role of stem cells in cancer progression.

DESIGN
Fifty-four surgical resections of IBD were studied. All
diagnoses were confirmed by at least two experienced
pathologists. The diagnostic categories were as follows:
13 high-grade dysplasia / adenocarcinoma, 19 low-grade
dysplasia, and 22 inflammatory atypia / negative for
dysplasia. Immunohistochemical staining for ALDH1 was
evaluated in the cytoplasm of epithelial and stromal cells
both on intensity (0-3+), and percentage of cells staining.
Criteria for positive staining was modeled after previous
work, requiring at least 1+ staining in >20% of cells to be
considered positive.
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Figure 1A: ALDH1 expression in dysplasia. Diffuse 3+ staining is present
throughout the dysplastic glands.
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Figure 1B: ALDH1 expression in adenocarcinoma. The invasive component
of this colitis-associated adenocarcinoma shows diffuse 3+ staining.

RESULTS
Patient demographics / follow-up
The study group had the following characteristics: 61% male
& 39% female, average age 50 years (range 25-82 years).
Total colectomy was performed in 83% of cases. Among
patients initially undergoing partial colectomy, 50% went on
to have a completion colectomy, while the remaining 50%
had surveillance biopsies showing features of inflammatory
disease without dysplastic change.

ALDH1 expression
Positive staining was seen in 92% of cases with high-grade
dysplasia / adenocarcinoma (12/13), and 95% (18/19) of cases
with low-grade dysplasia. Invasive carcinomas showed patchy
expression in 33% of cases, while dysplastic mucosa exhibited
homogeneous expression extending from the crypt base to
superficial mucosa (Figure 1A). Although patchy, staining of
invasive adenocarcinoma was generally strongest in the
advancing front (Figure 1B). A notable exception was a poorly
differentiated adenocarcinoma which failed to express ALDH1
(Figure 1C). Benign mucosa showed patchy focal positivity
mainly in the crypt base. Cases with inflammatory atypia
(negative for dysplasia) showed positive staining in 45%
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Figure 1C: ALDH1 expression in poorly-differentiated adenocarcinoma.
There is a complete lack of staining in the carcinoma, while the overlying
dysplastic mucosa shows diffuse 3+ staining.

(10/22) of cases (Figure 1D). Expression of ALDH1 in cases of
inflammatory atypia was concentrated in the crypt base in 20%
(2/10) of cases, and scattered throughout the crypt in 80% (8/10)
of cases. The sensitivity and specificity of ALDH1 for dysplasia
was 95% and 55%, respectively.

DISCUSSION
The rationale for our study was based upon the observation
that ALDH1 was both a sensitive and specific marker for
stem cells. Seventeen isoforms of aldehyde dehydrogenase
have been previously described from a wide distribution of
differentiated tissue, and with broad cellular distributions.
Highest levels are found in the liver, where ALDH1 functions
principally in the biosynthesis of retinoic acid. Although
retinoids are capable of inducing terminal differentiation in
late hematopoietic cells, immature cell populations exhibit
enhanced self-renewal in response to increased ALDH1
levels. An important step in the utilization of ALDH1 as a
surrogate marker of stem cells was to correlate its expression
with more accepted markers of stem cells. ALDH1+ cells
commonly co-express markers associated with a stem cell
phenotype including CD24, CD200, and Oct3/4. Given these
properties, it is not surprising increased ALDH1 expression

Figure 1D: ALDH1 expression in a case lacking dysplasia. This gland
shows architectural changes of IBD, however is negative for dysplasia.
ALDH1 staining shows 2+ expression in the inferior portion of the gland.

has been previously correlated with a poor prognosis in a
variety of epithelial malignancies.
The mechanism underlying colitis-associated adenocarcinoma
has been hypothesized to involve the generation of free
radicals and prooxidant molecules contributing to oncogenesis
through promotion of genomic instability. The pathways
targeted appear to mirror those involved in sporadic CRC,
and include allelic loss of tumor suppressor genes and
microsatellite instability. While not directly causative in these
processes, ALDH1 expression may provide a common link
between IBD and neoplasia, and ALDH1+ cells from areas of
inflammation have the ability to progress to CRC in xenograft
studies of NOD-SCID mice.

CONCLUSION
Our study demonstrates ALDH1 is significantly expressed in
dysplastic lesions arising from IBD. ALDH1-expression in
cancer stem cells suggests an important causative role in
the progression to cancer in IBD. Although we found high
sensitivity for dysplasia, the specificity was poor. In addition
to neoplasia, ALDH1-expressing stem cells proliferate in
response to chronic inflammation, accounting for the cases of
inflammatory atypia with positive ALDH1 expression.

